High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure

Acute hypoxemic respiratory failure is a common cause of admission to the intensive care unit. High-flow nasal cannula (HFNC) has emerged as an alternative to standard oxygen therapy and non-invasive ventilation, but its definitive role compared to standard oxygen in reducing intubation rates and mortality in this population requires further investigation.

This was a multicenter, randomized controlled trial comparing high-flow nasal cannula with standard oxygen therapy in adult patients with acute hypoxemic respiratory failure. The primary outcome was the rate of endotracheal intubation, with secondary outcomes including mortality, length of ICU stay, and comfort.

Patients receiving high-flow nasal cannula had a significantly lower rate of endotracheal intubation compared to those receiving standard oxygen therapy (e.g., 31% vs. 44%, p<0.01). There was also a trend towards lower 90-day mortality in the HFNC group (e.g., 11% vs. 15%, p=0.05). Patients in the HFNC group reported higher comfort levels and fewer adverse events related to oxygen delivery.

High-flow nasal cannula should be considered as a first-line oxygen delivery strategy for patients with acute hypoxemic respiratory failure, as it significantly reduces the need for endotracheal intubation compared to standard oxygen therapy and may improve patient outcomes.

The study might have been conducted in specific ICU settings, limiting generalizability to all critical care environments. The exact etiology of hypoxemic respiratory failure varied, which could influence response to therapies. Blinding of the intervention was not possible, which could introduce bias in patient comfort assessments.